Bristol-Myers Squibb Company v Apotex Pty Ltd

Link copied
Case Copied 77 min read

FEDERAL COURT OF AUSTRALIA

Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2

Citation: Bristol-Myers Squibb Company v Apotex Pty Ltd [2015] FCAFC 2
Appeal from:

Bristol-Myers Squibb Company v Apotex Pty Ltd (No 5) [2013] FCA 1114

Bristol-Myers Squibb Company v Apotex Pty Ltd (No 6) [2013] FCA 1235

Parties:

BRISTOL-MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO LTD v APOTEX PTY LTD ACN 096 916 148

APOTEX PTY LTD ACN 096 916 148 v BRISTOL‑MYERS SQUIBB COMPANY and OTSUKA PHARMACEUTICAL CO LTD

File numbers: NSD 2526 of 2013
NSD 2535 of 2013
Judges: BESANKO, JAGOT, NICHOLAS JJ
Date of judgment: 23 January 2015
Catchwords:

PATENTS – construction – where specification disclosed chemical substance – whether specification disclosed chemical substance with a particular crystalline form or a chemical substance having certain characteristics.

PATENTS – lack of novelty – whether invention claimed in patent anticipated by the prior art – whether the person skilled in the art would inevitably have taken particular drying steps required to create the invention in following directions in the prior art – whether the prior art discloses the particular crystalline form of chemical substance claimed and whether that disclosure discloses the properties of the invention claimed in the patent.

PATENTS – lack of inventive step – whether invention claimed in patent obvious – whether the person skilled in the art would have, as a matter of routine at the relevant time, dried chemical product in required manner to create particular chemical substance claimed – whether evidence of expert instructed to carry out experiment can satisfy the modified Cripps question.

PATENTS – exclusive licences – whether agreement between patentee and licensee an exclusive licence – where licensee granted exclusive rights to advertise, market, promote, sell and distribute invention, but patentee reserved exclusive rights to manufacture the invention – Patents Act 1990 (Cth) s 13(1), Schedule 1.

Held: Appeals dismissed. Patent not invalid. Licence not exclusive licence for purposes of the Patents Act 1990 (Cth).

Legislation: Patents Act 1949 (UK) s 101
Patents Act 1952 (Cth) s 95
Patents Act 1990 (Cth) ss 7, 13, 120, Schedule 1
Cases cited: Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416; [2009] FCAFC 134
AstraZenenca AB v Apotex Pty Ltd [2014] FCAFC 99
Blue Gentian LLC v Product Management Group Pty Ltd [2014] FCA 1331
Bristol-Myers Squibb Company v Apotex Pty Ltd (2010) 87 IPR 516; [2010] FCA 814
Bristol-Myers Squibb Company v Apotex Pty Ltd (No 4) [2012] FCA 1433
Evans Medical Ltd’s Patent [1998] RPC 517
Ex parte British Nylon Spinners Limited and Imperial Chemicals Industries Limited; In Re Imperial Chemical Industries Limited’s Patent (1963) 109 CLR 336
Fried v National Australia Bank [2000] FCA 910
Grant and Another v Australian Temporary Fencing Pty Ltd (2003) 59 IPR 170; [2003] QSC 194
H Lundbeck A/S v Alphapharm Pty Ltd (2009) 177 FCR 151; [2009] FCAFC 70
House v The King (1936) 55 CLR 499
ICI Chemicals & Polymers Ltd v The Lubrizol Corporation…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bristol-Myers Squibb Company v Apotex Pty Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] FCAFC 2
Decision Date

CaseChat Overview and Summary

The case of Bristol-Myers Squibb Company v Apotex Pty Ltd involved a dispute over the validity of a patent and the nature of an agreement between the parties. The matter was heard in the Federal Court of Australia. The primary issues before the court were the validity of the patent, whether the patent was anticipated by prior art, whether the invention lacked an inventive step, and whether the agreement between the parties constituted an exclusive licence under the Patents Act 1990.

The court had to determine whether the patent specification disclosed a chemical substance with a particular crystalline form or a chemical substance having certain characteristics. It also had to decide if the invention was anticipated by prior art and if the person skilled in the art would inevitably have taken particular drying steps required to create the invention. Additionally, the court needed to assess whether the invention lacked an inventive step and if the person skilled in the art would have, as a matter of routine, dried the chemical product in the required manner to create the particular chemical substance claimed. The court also had to consider whether expert evidence could satisfy the modified Cripps question. Lastly, the court examined whether the agreement between the parties constituted an exclusive licence under the Patents Act.

The court held that the appeals were dismissed and that the patent was not invalid. The court found that the agreement between the parties was not an exclusive licence for the purposes of the Patents Act. The court's reasoning was based on the interpretation of the definition of "exploit" and the nature of the rights granted under the agreement. The court concluded that the primary judge's construction of the word "exploit" was correct and consistent with the High Court's reasoning in British Nylon Spinners. The court also found that the agreement did not confer exclusive rights to manufacture the invention, which was a key factor in determining whether it was an exclusive licence.

The court's final orders were that the appeals be dismissed and that the appellants pay the respondents' costs of the appeal. The court emphasised that the entry of orders was dealt with in Rule 39.32 of the Federal Court Rules 2011.

Orders

Orders of the court

1. The appeal be dismissed.

2. The appellants pay the respondent’s costs of the appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

1. The appeal be dismissed.

2. The appellant pay the respondents’ costs of the appeal.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

We agree with that reasoning. We accept that, as BMS and Otsuka contended, it is possible to read the sections with the distributive definition of “exploit”, but we think the primary judge’s construction is the preferred one. In our opinion, the definition of the word “exploit” describes the content of a right and is not intended to create separate rights in relation to each of the identified activities. Once that conclusion is reached, the balance of the primary judge’s reasoning is entirely consistent with the reasoning of the High Court in British Nylon Spinners, and is, in our respectful opinion, correct. We would add with respect to what Holmes J said in Grant, that we do not agree that there is any relevant similarity between the definition of “exclusive licensee” in the 1990 Act and the definition in the English Act. In the latter Act, there is express reference to “any right in respect of the patented invention”. Furthermore, we do not think any particular significance is to be attached to the fact that the definition of the word “exploit” is inclusive and not exhaustive. The word “exploit” means the activities referred to in the definition, and such other activities as the Court holds (by the ordinary process of construction) fall within the meaning of “exploit”. It is open to the parties to an agreement to identify the right to exploit as the right which is the subject of the licence.5. CONCLUSIONS Apotex has not established any error by the primary judge. Accordingly, its appeal should be dismissed and it should pay the costs of BMS and Otsuka of its appeal. The appeal by BMS and Otsuka should also be dismissed and they should pay Apotex’s costs of their appeal.

Ratio Decidendi

Legal Principle Established